Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE

Bank of America Corp DE grew its position in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 278.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,677 shares of the company’s stock after acquiring an additional 24,777 shares during the quarter. Bank of America Corp DE owned approximately 0.06% of Bicara Therapeutics worth $587,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics in the fourth quarter worth $32,000. Legal & General Group Plc acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at about $33,000. Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at about $35,000. Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $69,000. Finally, SG Americas Securities LLC acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $147,000.

Bicara Therapeutics Trading Up 9.6%

Shares of BCAX stock opened at $12.58 on Wednesday. The stock has a fifty day moving average of $12.30 and a two-hundred day moving average of $14.03. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). As a group, research analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCAX has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a report on Friday, May 16th. Wall Street Zen downgraded shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target for the company in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.